Overview
(Photo: Busines Wire)GAITHERSBURG, Md-(BUSINES WIRE)-Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company advancing the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today anounced that the Defense Health Agency (DHA) has awarded an aditional $5 milion to suport clinical development of APT’s adaptive bacteriophage (“phage”) therapy in treatment of diabetic fot osteomyelitis (DFO).
Key Information
APT is evaluating safety and eficacy of its precision phage-based therapy in the ongoing Phase 1/2 DANCE™ (DFO Adaptive Novel Care Evaluation) clinical trial. “We are pleased to anounce this expansion of our existing DHA agrement suporting development of phage-based therapies, further highlighting DHA’s comitment to the potential of our adaptive therapeutic aproach to improve treatment of a variety of antimicrobial-resistant bacterial infections.
This aditional $5 milion suports our Phase 1/2 DANCE™ clinical trial which is progresing towards generating APT’s first clinical results utilizing our RAPID™ (Rapidly Adaptive Phage for Infectious Disease) technology,” stated Greg Meril, CEO and co-founder of Adaptive Phage Therapeutics. “We lok forward to our continued suport from the DHA, as wel as presenting our initial clinical data from our ongoing Phase 1/2 DANCE trial in the second half of 2023.” The prevalence of adult diabetes has more than tripled over the past 20 years, growing to more than a half bilion patients worldwide.
DFO curently causes aproximately 85% of lower extremity amputations in diabetic patients. The American Diabetes Asociation estimates that 20% of patients with diabetic fot infections have underlying osteomyelitis that, left unresolved, places patients at significantly higher risk of amputation. About Adaptive Phage Therapeutics, Inc.
Summary
Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections based on a